1 Min Read
Dec 14 (Reuters) - Medivir AB
* Medivir’s fusion inhibitor for the treatment of respiratory syncytial virus infection, MIV-323, enters non-clinical development Source text for Eikon: Further company coverage: (Stockholm Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.